Journey Medical (DERM) Revenue & Revenue Breakdown


OverviewOwnershipFinancialsChartTranscripts

Journey Medical Revenue Highlights


Latest Revenue (Y)

$79.18M

Latest Revenue (Q)

$14.86M

Main Segment (Y)

Qbrexza

Journey Medical Revenue by Period


Journey Medical Revenue by Year

DateRevenueChange
2023-12-31$79.18M7.48%
2022-12-31$73.67M16.69%
2021-12-31$63.13M41.78%
2020-12-31$44.53M27.52%
2019-12-31$34.92M-17.52%
2018-12-31$42.34M832.37%
2017-12-31$4.54M-79.89%
2016-12-31$22.59M209.38%
2015-12-31$7.30M-
2014-12-31$7.30M-

Journey Medical generated $79.18M in revenue during NA 2023, up 7.48% compared to the previous quarter, and up 187.02% compared to the same period a year ago.

Journey Medical Revenue by Quarter

DateRevenueChange
2024-06-30$14.86M14.01%
2024-03-31$13.03M-14.60%
2023-12-31$15.26M-55.83%
2023-09-30$34.54M101.14%
2023-06-30$17.17M40.60%
2023-03-31$12.21M-23.51%
2022-12-31$15.97M-0.93%
2022-09-30$16.12M-11.89%
2022-06-30$18.29M-21.48%
2022-03-31$23.30M32.99%
2021-12-31$17.52M-10.67%
2021-09-30$19.61M28.27%
2021-06-30$15.29M42.63%
2021-03-31$10.72M-21.89%
2020-12-31$13.72M45.26%
2020-09-30$9.45M0.34%
2020-06-30$9.41M-11.85%
2020-03-31$10.68M-7.39%
2019-09-30$11.53M-82.69%
2019-06-30$66.64M2617.99%
2019-03-31$2.45M9.32%
2018-12-31$2.24M212.83%
2018-09-30$717.00K-98.17%
2018-06-30$39.08M12970.23%
2018-03-31$299.00K-77.74%
2017-12-31$1.34M25.98%
2017-09-30$1.07M-
2017-06-30$1.07M-
2017-03-31$1.07M-95.26%
2016-12-31$22.47M18778.99%
2016-09-30$119.00K100.00%
2016-06-30-100.00%
2016-03-31--100.00%
2015-12-31$7.30M-
2015-09-30$7.30M100.00%
2015-06-30-100.00%
2015-03-31--100.00%
2014-12-31$7.30M-

Journey Medical generated $14.86M in revenue during Q2 2024, up 14.01% compared to the previous quarter, and up 121.63% compared to the same period a year ago.

Journey Medical Revenue Breakdown


Journey Medical Revenue Breakdown by Product

Annual Revenue by Product

Product/ServiceDec 23Dec 22Dec 21
Exelderm$2.40M$3.46M$5.36M
Accutane$20.17M$18.37M$10.05M
Amzeeq$6.20M$7.24M-
Zilxi$1.96M$2.27M-
Ximino$287.00K$4.96M$8.25M
Targadox$3.20M$7.97M$22.38M
Qbrexza$25.41M$26.71M-
Other Branded Products--$37.00K
Qbrexa--$17.06M

Journey Medical's latest annual revenue breakdown by segment (product or service), as of Dec 23: Qbrexza (42.61%), Accutane (33.82%), Amzeeq (10.40%), Targadox (5.37%), Exelderm (4.02%), Zilxi (3.29%), and Ximino (0.48%).

Quarterly Revenue by Product

Product/ServiceJun 24Mar 24Dec 23Jun 23Dec 22Sep 22Jun 22Mar 22Dec 21Sep 21
Amzeeq$1.21M$755.00K$1.35M$1.16M$1.26M$3.47M----
Zilxi$369.00K$273.00K$422.00K$554.00K$555.00K$741.00K----
Qbrexza$6.84M$5.02M$17.33M$8.08M$6.96M$6.26M----
Accutane$5.72M$5.82M$14.59M$5.58M$4.14M$4.12M$5.20M$4.91M$4.38M$3.53M
Ximino----$1.18M$1.77M$1.03M$967.00K$1.97M$2.86M
Exelderm----$445.00K$1.00M$1.31M$704.00K$1.04M$1.37M
Targadox----$1.41M$1.17M$2.76M$2.63M$4.27M$5.18M
Qbrexa------$6.11M$7.38M$5.85M$6.64M
Other Branded Products-------$1.00K$2.00K$29.00K

Journey Medical's latest quarterly revenue breakdown by segment (product or service), as of Jun 24: Qbrexza (48.38%), Accutane (40.48%), Amzeeq (8.53%), and Zilxi (2.61%).

Journey Medical Peer Comparison by Revenue


TickerCompanyLast Year RevenueLast Quarter Revenue
ORGOOrganogenesis$433.14M$130.23M
ACBAurora Cannabis$233.29M$64.42M
LFCRLifecore Biomedical$128.26M$24.70M
ALIMAlimera Sciences$80.75M$23.01M
DERMJourney Medical$79.18M$14.86M
AQSTAquestive Therapeutics$50.58M$20.10M
AVDLAvadel Pharmaceuticals$27.96M$41.50M
JUPWSafety Shot$6.20M$910.01K
EVOKEvoke Pharma$5.18M$1.74M
LSDILucy Scientific Discovery$7.05K$9.68K
SHPHShuttle Pharmaceuticals--

DERM Revenue FAQ


Journey Medical's yearly revenue for 2023 was $79.18M, representing an increase of 7.48% compared to 2022. The company's yearly revenue for 2022 was $73.67M, representing an increase of 16.69% compared to 2021. DERM's yearly revenue for 2021 was $63.13M, representing an increase of 41.78% compared to 2020.

Journey Medical's quarterly revenue for Q2 2024 was $14.86M, a 14.01% increase from the previous quarter (Q1 2024), and a -13.49% decrease year-over-year (Q2 2023). The company's quarterly revenue for Q1 2024 was $13.03M, a -14.60% decrease from the previous quarter (Q4 2023), and a 6.69% increase year-over-year (Q1 2023). DERM's quarterly revenue for Q4 2023 was $15.26M, a -55.83% decrease from the previous quarter (Q3 2023), and a -4.44% decrease year-over-year (Q4 2022).

Journey Medical's revenue growth rate for the last 3 years (2021-2023) was 25.42%, and for the last 5 years (2019-2023) was 126.74%.

Journey Medical's revenue streams in c 23 are Exelderm, Accutane, Amzeeq, Zilxi, Ximino, Targadox, and Qbrexza. Exelderm generated $2.4M in revenue, accounting 4.02% of the company's total revenue, down -30.84% year-over-year. Accutane generated $20.17M in revenue, accounting 33.82% of the company's total revenue, up 9.77% year-over-year. Amzeeq generated $6.2M in revenue, accounting 10.40% of the company's total revenue, down -14.37% year-over-year. Zilxi generated $1.96M in revenue, accounting 3.29% of the company's total revenue, down -13.68% year-over-year. Ximino generated $287K in revenue, accounting 0.48% of the company's total revenue, down -94.21% year-over-year. Targadox generated $3.2M in revenue, accounting 5.37% of the company's total revenue, down -59.81% year-over-year. Qbrexza generated $25.41M in revenue, accounting 42.61% of the company's total revenue, down -4.88% year-over-year.

For the fiscal year ending Dec 23, the largest source of revenue of Journey Medical was Qbrexza. This segment made a revenue of $25.41M, representing 42.61% of the company's total revenue.